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Abstract
Purpose Decision aids (DAs) support patients in shared decision-making by providing balanced evidence-based treatment 
information and eliciting patients’ preferences. The purpose of this systematic review was to assess the quality and com-
municative aspects of DAs for women diagnosed with early-stage breast cancer.
Methods Twenty-one currently available patient DAs were identified through both published literature (MEDLINE, Embase, 
CINAHL, CENTRAL, and PsycINFO) and online sources. The DAs were reviewed for their quality by using the International 
Patient Decision Aid Standards (IPDAS) checklist, and subsequently assessed to what extent they paid attention to various 
communicative aspects, including (i) information presentation, (ii) personalization, (iii) interaction, (iv) information control, 
(v) accessibility, (vi) suitability, and (vii) source of information.
Results The quality of the DAs varied substantially, with many failing to comply with all components of the IPDAS criteria 
(mean IPDAS score = 64%, range 31–92%). Five aids (24%) did not include any probability information, 10 (48%) presented 
multimodal descriptions of outcome probabilities (combining words, numbers, and visual aids), and only 2 (10%) provided 
personalized treatment outcomes based on patients and tumor characteristics. About half (12; 57%) used interaction methods 
for eliciting patients’ preferences, 16 (76%) were too lengthy, and 5 (24%) were not fully accessible.
Conclusions In addition to the limited adherence to the IPDAS checklist, our findings suggest that communicative aspects 
receive even less attention. Future patient DA developments for breast cancer treatment should include communicative 
aspects that could influence the uptake of DAs in daily clinical practice.
Keywords Breast cancer · Decision aids · Patient education · Risk communication · Shared decision-making · Treatment 
decision-making
Abbreviations
DA  Decision aid
IPDAS  International patient decision aids standards
SDM  Shared decision-making
Introduction
In early breast cancer care, there has been rapid growth in the 
development of patient decision aids (DAs) to support the 
process of shared decision-making (SDM) between patients 
and their clinician [1]. DAs are tools (aimed at patients and 
distributed by clinicians) that provide information about 
treatment options and associated risks of side-effects and 
disease recurrence, and help patients clarify their values 
and preferences [2, 3]. Moreover, DAs should encourage 
patients to (actively) participate in the SDM process with 
their clinician [3, 4]. Despite great promise and the increas-
ing interest in developing DAs [1, 2], the extent to which 
they are implemented into daily clinical practice appears to 
be limited [5, 6].
One reason for this might be the variability in the 
characteristics and quality of DAs for early breast cancer 
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treatment [7]. Assessing the quality of DAs (e.g., whether 
the DAs’ content is reliable and evidence-based, or how 
they were developed and field-tested) is relevant to patients 
and clinicians [8], since a lack of trust in or familiarity 
with the quality of DAs could explain why clinicians do 
not distribute them to their patients [9]. Typically, the 
validated international patient decision aids standards 
(IPDAS) checklist is used to ensure the quality of DAs 
[10], and covers a variety of dimensions, ranging from 
information about treatment options and outcome prob-
abilities to decision guidance and development process. 
Although the IPDAS is considered the gold standard for 
developing and evaluating DAs [11], being IPDAS com-
pliant does not guarantee that DAs will reach the hands 
of patients.
We argue that another factor is the extent to which DAs 
pay attention to the communicative aspects. In fact, DAs 
include many communication aspects that may influence 
the use and understanding of the tools by patients and cli-
nicians, but are not covered by the IPDAS checklist [12]. 
These include, for instance, how DAs present information 
about treatment options and associated outcome prob-
abilities to patients (e.g., only words or numbers, or in 
combination with visual aids) [13], or how they communi-
cate uncertainty around statistics. Another communicative 
aspect is how DAs interact with patients to elicit their val-
ues or preferences (e.g., value-clarification exercise) [14], 
or to provide patients with personalized information based 
on their personal and tumor characteristics (e.g., personal-
ized risk or survival estimates), all of which can improve 
patient and clinician’s understanding of the personal and 
clinical situation at hand. Furthermore, aspects like the 
suitability (e.g., complex language use), accessibility (e.g., 
only internet-based), or source of information (e.g., reli-
able outcome probabilities) could disturb the communica-
tion process between the DA, patient, and clinician [15]. 
All these aspects are important elements of the commu-
nication process [16], and DAs that pay less attention to 
these aspects may limit their ability to be distributed by 
clinicians and to be used and/or comprehended by patients.
Although some reviews have shown the effectiveness of 
DAs in early breast cancer care [1, 17, 18], there has been 
no review on the quality and use of communicative aspects 
among existing DAs for patients facing early breast cancer 
treatment decisions. Therefore, the aims of this systematic 
review were (1) to make an inventory of currently avail-
able patient DAs for early-stage breast cancer treatment 
in both English and Dutch, (2) to critically review their 
quality based on the IPDAS criteria, and (3) to assess to 
what extent they pay attention to various communicative 
aspects.
Methods
This systematic review is conducted and reported in com-
pliance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [19].
Data sources and search strategy
A systematic search of both published literature and online 
sources was conducted to identify and obtain DAs for 
patients facing early breast cancer treatment decisions. 
To obtain DAs with associated studies through published 
literature, we searched the following databases: MED-
LINE (via PubMed), EMBASE, Cochrane Library, The 
Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), and PsycINFO. Given that the IPDAS checklist 
was launched in 2006, we searched the databases from Janu-
ary 2006 until March 2018. Reference lists and author names 
were searched to identify additional publications that met the 
eligibility criteria. The search strategy included a combina-
tion of keywords, synonyms, and MeSH headings relating 
to the concepts of breast cancer, DAs, SDM, and treatments 
(Supplementary Material 1). To obtain DAs without associ-
ated studies through online sources, we searched the Ottowa 
Decision Aid Library Inventory (https ://decis ionai d.ohri.ca/
cochi nvent .php), and  GoogleTM (search terms “decision aid,” 
“breast cancer,” and “treatment”) in both Dutch and English 
for which the first 100 hits were analyzed.
Inclusion and exclusion criteria
We developed inclusion and exclusion criteria for the iden-
tification of scientific studies and for decision aids. For the 
studies obtained through published literature, the inclusion 
criteria include those that were (1) reported in a scientific 
journal (peer-reviewed); (2) published between 2006 and 
2018; (3) written in English or Dutch. Study types eligible 
for inclusion were (1) (non-)randomized controlled trials or 
experimental studies that addressed the impact of DAs as 
intervention on decisional outcomes or treatment choice; (2) 
development and/or evaluation of the DAs (e.g., protocol, 
developmental, evaluation, usability testing, or observational 
studies). Target populations of studies included newly diag-
nosed patients with early-stage breast cancer facing treat-
ment decision-making.
For both DAs obtained through published literature and 
online sources, the following exclusion criteria applied: 
DAs (1) developed for women with advanced stages of 
breast cancer or for breast cancer screening; (2) in the for-
mat of predictive or decision-support tools (e.g., Predict-
UK, Adjuvant!Online) since such tools are aimed for both 
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clinician and patients; (3) in the format of phone calls, online 
support groups, interviews, nomograms, or audiotapes, since 
such formats could not be analyzed. Finally, the following 
inclusion criteria applied: DAs that were (1) published 
between 2006 and 2018; (2) (publicly) available; (3) fully 
accessible (e.g., no monetary costs associated with the DA 
such as one time purchase, or no need to be prescribed by a 
certain healthcare system or clinician); (4) written in English 
or Dutch.
Study and decision aid selection
Two reviewers (RV, KT) screened all retrieved articles for 
relevance based on title and abstract for initial eligibility. 
The overall kappa score for inter-rate agreement during the 
screening phase was strong (κ = 0.97) [20]. Afterwards, 
the few disagreements were resolved through discussion or 
adjudication by a third person. Subsequently, the same two 
reviewers independently evaluated the articles that passed 
the previous screening phase based on the eligibility crite-
ria and disagreements were resolved through discussion and 
consensus between the two reviewers. The overall kappa 
score during the study eligibility phase was strong (κ = 0.91). 
Data extraction of the included studies and DAs were inde-
pendently assessed by two reviewers.
Assessment of decision aids
The assessment of the identified DAs consisted of two parts. 
DAs were first reviewed for their quality according to IPDAS 
criteria, after which they were critically assessed on a com-
municative aspect checklist. Each DA was independently 
assessed by two coders (four coding teams in total). Inter-
rate agreements (κ) achieved by the teams ranged from 0.74 
to 0.86 for the IPDAS checklist (mean κ = 0.81), and from 
0.76 to 0.90 for the assessment of CAs (mean κ = 0.83). The 
total, average inter-rate agreement was good (κ = 0.82).
Quality of decision aids
Quality of the included DAs was assessed by using the 
IPDAS Collaboration criteria framework. The IPDAS 
instrument (Supplementary Material 2) [10] consists of 36 
items divided into eight dimensions: (i) information about 
options (items 1–8), (ii) outcome probabilities (items 
9–16), (iii) clarifying values (items 17–20), (iv) decision 
guidance (items (21–22), (v) development process (items 
23–28), (vi) using evidence (items 29–33), (vii) disclo-
sure and transparency (items 34–35), and (viii) plain lan-
guage (item 36). Since not all DAs had been evaluated 
in scientific studies, we decided to exclude the two items 
related to the evaluation dimension. Response options for 
each criteria item were ‘yes’ and ‘no’ (coded as 1 and 0, 
respectively). For each DA, the number of IPDAS items 
met was converted to percentages of the total number of 
items.
Communicative aspects of decision aids
The use of communicative aspects by the DAs was 
assessed by a recently developed and validated commu-
nicative aspect checklist for patient DA (Supplementary 
Material 3) [12]. This tumor-independent checklist con-
sists of 76 items divided into seven CAs: (i) information 
presentation (items 1–26), (ii) information control (items 
27–33), (iii) personalization (items 34–40), (iv) interac-
tion (items 41–55), (v) accessibility of information (items 
56–64), (vi) suitability of information (65–68), and (vii) 
source of information (items 69–76). Response options for 
each item were ‘yes’ and ‘no’ (coded as 1 and 0, respec-
tively; seven items needed to be recoded). Since six items 
were only applicable to web-based DA, the total number of 
items for paper-based DAs was 70, and for web-based 76. 
For each DA, the number of communicative aspect items 
met was converted to percentages of the total number of 
items. Note that a higher communicative aspects score 
does not necessarily indicate a higher quality DA; it only 
suggests that more items from the communicative aspects 
checklist were taken into consideration.
Results
Search results and decision aid characteristics
In total, 8073 records were identified through five databases, 
and four additional records through other sources (Fig. 1). 
Screening titles, abstracts, and full-texts yielded ten eli-
gible studies, including seven unique DAs. An additional 
search through online sources resulted in another 14 unique 
DAs, leading to a total of 21 DAs included in this review 
(Table 1). Ten aids originated from the United States, five 
from the Netherlands, five from Australia, and one from 
Canada. Eleven of the DAs were web based and ten were 
paper based. Most DAs discussed reconstruction surgery 
(11) and/or surgery (10; mastectomy vs. breast-conserving 
therapy) as treatment options, followed by (adjuvant) radio-
therapy (9), systemic therapy (7; (neo)adjuvant chemother-
apy and hormonal therapy), and lymph node surgery (3; axil-
lary dissection and sentinel node biopsy). Year of last update 
ranged from 2008 to 2018, but most (13) had been updated 
in 2017 or 2018. Seven DAs had 1 or more associated stud-
ies [21–30] of which three were RCTs, five evaluation and/
or development studies, and two protocol studies (Table 2).
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Quality of decision aids
None of the DAs met all of the IPDAS criteria, and the total 
percentage of IPDAS criteria met by the DAs ranged from 
31 to 92% (mean IPDAS score (M) = 64%, standard devia-
tion (SD = 20%), see Fig. 2). The seven DAs with associ-
ated studies had slightly higher IPDAS scores (M = 68%, 
SD = 8%) than DAs without associated studies (M = 63%, 
Fig. 1  Flowchart of study and decision aid selection process
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SD = 5%). The best performing DAs on the IPDAS checklist 
were DA12, DA14, and DA20 (Fig. 3).
Most aids showed high performance on the dimensions 
information about treatment options, clarifying values, 
disclosure and transparency, and decision guidance. For 
instance, all DAs (100%) presented the available treatment 
options, with the majority of them explaining both positive 
and negative features of the options (95%). All aids asked 
patients to think about positive and negative features of the 
options that matter most to them (100%). Mixed perfor-
mance was observed for items related to evidence, develop-
ment process, and outcome probabilities. For instance, as 
mentioned by the DA or associated paper, almost all aids 
were reviewed by doctors (95%), but only half of them were 
reviewed by (52%) or tested with (57%) patients. Five aids 
(24%) did not contain any outcome probabilities. Of the 
aids that did contain probability information, many did not 
adhere to good practice guidance on communicating essen-
tial elements such as providing event rates (57%), keeping 
the same denominators (29%), reporting time period (43%), 
or uncertainty (52%). Moreover, only four DAs (19%) 
reported the update policy and three (14%) discussed the 
quality of the evidence used. Finally, regarding the dimen-
sion of plain language, only five aids (24%) reported accept-
able readability levels (e.g., 8th–10th grade (Flesch-Kincaid) 
reading level).
Communicative aspects of decision aids
A full summary of the results on the assessment of commu-
nicative aspects can be found in Supplementary Material 3. 
The overall percentage of communicative aspect items met 
by the DAs ranged from 31% to 68% (M = 52%, SD = 10%). 
The seven DAs with associated studies had similar com-
municative aspects scores (M = 52%, SD = 5%) compared 
to DAs without associated studies (M =52%, SD = 2%). The 
best performing DAs on the communicative aspects check-
list were DA9, DA20, and DA21 (Fig. 3). In general, the 
majority of the aids met most items related to accessibility; 
mixed results were found for items with respect to informa-
tion presentation, information control, interaction, and suit-
ability of information; the least number of items met was 
shown for personalization and source of information (Fig. 4).
Information presentation
All DAs used different presentation formats for communicat-
ing outcome probabilities. Of the aids, 3 (14%) did not use 
any method, 2 (10%) used words-only (e.g., verbal descrip-
tions), 6 (29%) used a combination of words and numbers, 
and 10 (47%) applied a combination of words, numbers, 
and visuals. Of the 16 aids that used numerical methods, 
natural frequencies were most often used (12; 75%) followed Ta
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Fig. 2  The international patient decision aid standard (IPDAS) scores for each decision aid. Decis guidan decision guidance, D&T disclosure 
and transparency, PL plain language
Fig. 3  Percentage of items met 
on the IPDAS and communica-
tive aspects checklist for each 
decision aid. Decision aids are 
presented in chronological order 
(based on year of last update)
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by percentages (11; 69%); for the 10 aids that used visual 
methods, icon arrays were the most common (9; 90%), fol-
lowed by a pie chart or line graph (both 1; 10%). Of the 18 
aids that communicated probability information, 14 (78%) 
described uncertainties around them, typically with verbal 
methods (13; 93%), followed by numerical ranges (8; 57%), 
and visually presented confidence intervals (1; 7%). Varia-
tions were also observed in presenting disease-related infor-
mation (6 used text-only, 10 a combination of text and vis-
ual/audiovisual), and procedures of treatments (6 text-only, 
15 a combination of text and visual/audiovisual). Finally, 
a significant number of DAs (19; 90%) presented informa-
tion in an unbalanced way; 9 aids (43%) used more space/
text for a specific treatment option, the majority provided an 
unequal number of positive (12; 55%) and negative features 
(17; 85%) across the treatment options, and of the 16 aids 
that included statistical information only 5 (31%) displayed 
such statistics in a similar way for each option.
Personalization
The majority of the DAs (14; 67%) were tailored towards 
the breast cancer stage (e.g., early-stage). However, tailor-
ing towards the type of treatment (7; 33%), specific popula-
tions (3; 14%), or other breast cancer-related factors (4; 19%) 
(e.g., HER2 status) occurred less frequently. Five aids (24%) 
allowed patients to tailor the content of the DA, 3 (14%) to 
tailor information to patients’ own preference for the mode 
of information presentation, and only 2 DAs (10%) allowed 
patients to view individualized outcome probabilities based 
on their own situation.
Interaction
Several interaction methods had been used by the DAs. For 
comparing treatment options (20; 95%), most used side-by-
side tables or verbal comparisons (both 17; 85%), 6 (30%) 
Fig. 4  Violin plots of the 
percentage of items met on the 
communicative aspects check-
list separated for each aspect. 
For each violin plot, dark dots 
represent the DAs
 Breast Cancer Research and Treatment
1 3
included ranking or rating exercises, and 2 (10%) applied 
conjoint analysis/visual analogue scales based on patients’ 
preferences. For clarifying patients’ values, the majority (20; 
95%) passively asked patients to think about their personal 
values, and about half used active methods such as weight-
ing exercises (12; 60%) and/or sliders to assign values to 
preferences (9; 45%). Feedback was also given in different 
ways. Twelve aids (57%) showed the progress of the aid, 12 
(57%) provided a summary of patients’ values and prefer-
ences, 17 (81%) included a print option. About half (10; 
48%) provided space for note taking, and 8 (38%) included 
a knowledge test.
Information control
Nine aids (43%) allowed patients to only receive information 
that they wanted to read. The majority (18; 86%) provided 
a step-by-step way to move through the DA, and 16 (76%) 
gave patients the opportunity to read more about a specific 
topic of interest. Only 5 aids (24%) allowed for patients to 
search for specific keywords or topics in the aid.
Accessibility and suitability
Regarding the suitability of information, almost all DAs (19; 
90%) used a conversational (writing) style, and only 6 (29%) 
contained irrelevant illustrations that did not have any link 
with the messages being presented. Of the aids that included 
audiovisual material, only 1 (17%) had videos of less than 
1 min. Most aids (16; 76%) were lengthy and contained more 
than ten (web) pages. Regarding accessibility of the aids, 
16 (76%) were freely available on the web, and 5 (24%) 
required a login code to get full access. Thirteen DAs (62%) 
reported the date of last update, but only 2 (10%) reported 
the update frequency. All except for 1 aid could be used on 
multiple devices such as a laptop or smartphone, or were 
self-administered. Six aids (29%) required staff assistance 
in order to start with the aid.
Source of information
Of the 18 DAs that communicated outcome probabilities, 
most included probabilities for treatment side-effects (12; 
67%), followed by recurrence of cancer (12; 67%). Numeri-
cal information related to survival rates (4; 22%) or quality 
of life outcomes (5; 28%) occurred less frequently. Only 5 
DAs (28%) reported the original source of the probabilities 
(e.g., RCTs or population-based data), of which 3 (60%) pro-
vided detailed information about the patients included in the 
data (sets) and 1 (20%) about the period of data collection.
Discussion
In this systematic review, we identified 21 currently avail-
able patient DAs for early-stage breast cancer treatment, 
and critically reviewed their quality (as assessed by the 
IPDAS checklist [10]) and use of communicative aspects 
(as assessed by a communicative aspect checklist [12]). 
This review shows substantial variability in the quality 
of the DAs, with no existing DA meeting all of the inter-
nationally agreed IPDAS criteria. Many did not adhere to 
good practice guidance on providing information about 
the development, evidence used for the content, or report-
ing readability levels. This limited adherence to the qual-
ity criteria has also been found among existing DAs for 
patients with localized prostate cancer [7, 12]. Never-
theless, it is promising to see that most of the recently 
launched or updated DAs in our review (i.e., from 2017 
onwards) have shown increased adherence to the IPDAS 
criteria (see Fig. 3), which suggests that current DA devel-
opers and/or clinicians are now taking these criteria much 
more into account than in the past. At the same time, how-
ever, patients can still easily find and make use of existing 
low-quality DAs, which may foster low implementation 
rates [5, 6].
We also observed that few DAs presented a thorough 
description of outcome probabilities of treatment options. 
In fact, three aids did not contain any probability infor-
mation at all, and two only used verbal descriptions. Ide-
ally, treatment decision-making is, among other elements 
such as patients’ preferences, guided by evidence-based 
probabilities of treatment outcomes such as survival rates, 
side-effects, or quality of life after treatment [3, 13]. Fol-
lowing the IPDAS guidelines, such outcomes may help 
newly diagnosed cancer patients in balancing the risks and 
benefits of options together with their clinician, and should 
therefore be incorporated in DAs [31]. Moreover, from 
an ethical point of view, patients should be fully and ade-
quately  informed3, and thus they should also be informed 
about outcome probabilities and their original sources 
[32]. The lack of statistical information for breast cancer 
DAs is remarkable and in contrast with DAs evaluated for 
men with localized prostate cancer of which all (except for 
one DA) contained numeric estimates regarding survival 
rates and side-effects of treatments [12].
The DAs that did communicate probability informa-
tion showed great variability in how they communicated 
such statistical information. Most aids used numeric esti-
mates such as natural frequencies or percentages, and 
only a few used visual aids such as icon arrays. However, 
several studies have shown that patients (especially with 
low numeracy skills) often misunderstand such statistics 
[33], especially when only being communicated in words 
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[34]. Adding numbers in combination with visual aids 
may facilitate patients’ understanding of probabilities and 
overcome several biases such as denominator neglect or 
framing effects [13]. This multimodal strategy (e.g., using 
both words and pictures) is also useful for communicat-
ing other treatment information (e.g., procedures of treat-
ments), which may lead to better information recall by 
patients [35]. Over the years, several best practices in the 
communication of evidence-based outcome probabilities 
have been developed [13, 33], and it is important that DA 
developers and clinicians who are communicating statisti-
cal information to patients are taking these sets of guiding 
principles into account.
One of the more significant communicative issues found 
in the reviewed DAs for early breast cancer concerns the 
lack of personalization. For instance, all (except for two) 
DAs communicated average outcome probabilities based on 
statistics of groups of prior patients, which may be difficult 
to apply to the situation of individual patients [36]. Clinical 
decision-support tools for explaining chemotherapy survival 
benefits exist (e.g., Predict-UK), and can already estimate 
personalized outcomes based on patients’ personal (e.g., age) 
and disease-related (e.g., tumor stage) characteristics entered 
by the clinician. However, such tools are often difficult to 
understand for patients and should always be used in consul-
tation with a clinician. We therefore argue that patient DAs 
can be improved by incorporating patient-friendly versions 
(or result pages) of such personalized clinical prediction 
models into existing or novel DAs. However, a prerequisite 
for personalizing outcomes to individual patients is the avail-
ability of robust predictive models based on large amounts 
of clinical data [37, 38]. Recent technological advances in 
data science and artificial intelligence in combination with 
large population-based (e.g., cancer registries) or patient-
reported outcome datasets offer promise for the generation 
of personalized treatment outcomes in DAs [12, 39].
This review further reveals some potential commu-
nicative issues of early breast cancer-specific DAs that 
could hinder their uptake in routine clinical practice. 
For instance, most aids provided extensive and detailed 
information about the options. This may be beneficial for 
patients who prefer detailed information about treatment 
options, but may discourage patients who do not have the 
need, time, or capacity for this [40]. Similarly, not all DAs 
were easily accessible for patients due to, for instance, lim-
ited access (i.e., login code), out-datedness of information, 
or poor findability. These accessibility issues might be bar-
riers for especially patients with low literacy skills, who 
face difficulty in finding, evaluating, and obtaining online 
health information [41]. Next to that, clinicians may better 
appreciate the benefit of using and providing DAs to their 
patients if communicative aspects such as personalization 
(e.g., individualized treatment outcomes) or interaction 
(e.g., value-clarification exercises) are taken into account. 
Clinicians may wonder how a limited DA can add to their 
advisory consult and whether a low literacy patient can 
take advantage of this DA. It is plausible that improving 
these communicative aspects of DAs will lower the barrier 
for clinicians to distribute DAs to their patients.
Our review does have some limitations. First, most DAs 
were identified through online sources compared to the 
academic literature. Initially, we found 26 DAs with asso-
ciated studies, which was comparable with the number of 
studies found by a related review [1]. In contrast with that 
review, we needed to have full access to the tools in order to 
accurately review their quality and communicative aspects. 
Hence, we could only obtain full access to a minority of 
those aids found through the academic sources. It should be 
noted, though, that this distribution of aids found via pub-
lished literature or online sources is similar to distributions 
found in related reviews [7, 12], that used a similar method 
for identifying and reviewing the characteristics of DAs. 
Another limitation is that we could not link the IPDAS and 
communicative aspect scores to various SDM outcomes, 
mostly because of the lack of data. For instance, it may be 
that DAs that are personalized (in terms of content, amount 
of information, or mode of information delivery) are seen 
as more personally relevant and processed more deeply by 
patients [42]. The benefit of this in-depth processing is that 
patients may acquire better knowledge about their options, 
which makes them better prepared for their next consulta-
tion, with more time actively involved in a SDM process 
[43].
Conclusion
SDM in early breast cancer care requires that patient and 
clinician are both well-informed about the clinical case and 
personal situation at hand. DAs have been developed to 
facilitate this process, but their implementation in routine 
clinical practice remains low. This review provides insights 
into the variability among currently available DAs for early 
breast cancer treatment, and shows that both their quality 
and use of various communicative aspects can be improved. 
In addition, even though adherence to the IPDAS checklist is 
important for ensuring high-quality DAs, our findings sug-
gest that DA developers should also seriously consider com-
municative aspects that could influence the uptake of DAs 
in daily practice. Our results do not only have implications 
for clinicians who are involved in the development and use 
of DAs for breast cancer treatment, but also for clinicians 
outside of breast cancer who are facing similar complex and 
time-consuming clinical counseling scenarios with their 
patients.
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